Compare Gilead Sciences, Inc. (GILD) vs General Mills, Inc. (GIS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs General Mills, Inc. — how do they compare? Gilead Sciences, Inc. trades at $146.25 (market cap $182.40B), while General Mills, Inc. trades at $32.37 (market cap $17.43B). The key difference: Gilead Sciences, Inc. is far larger — about 10.5× General Mills, Inc.'s market cap, and General Mills, Inc. pays the higher dividend (7.49%). Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and General Mills, Inc. for 106 Days on average.
| GILD | GIS | |
|---|---|---|
Market Cap | $182.40B | $17.43B |
Volume | 4,469,821 | 16,554,362 |
Sector | Health | Consumer Staples |
52-Week High | $155.80 | $49.36 |
52-Week Low | $116.74 | $31.67 |
Typical Hold Time | 111 Days | 106 Days |
Enterprise Value | $205.46B | $30.61B |
Dividend Yield | 2.23% | 7.49% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $146.85, up 1.82% today, with a bullish technical signal from moving averages and recent earnings beats in Q4 2025 and Q1 2026. The company reported strong 2025 revenue of $29.44B and net income of $8.51B, though 2026 projections show a net loss. Key developments include a partnership with PAHO to expand HIV prevention drug access in Latin America, supporting long-term growth prospects amid mixed profitability metrics.
The outlook for GILD is cautiously optimistic, driven by analyst consensus favoring a buy rating (65.52%) and a price target of $151.57. Opportunities lie in HIV and oncology pipeline advancements, but risks include negative 2026 profit margins and high debt levels. Investors should weigh strong cash flow from operations against execution risks in a competitive biopharma landscape.
General Mills (GIS) trades at $31.77, down 1.27% with bearish technical signals despite beating Q2 2026 EPS estimates. The stock shows attractive valuation metrics with P/E of 9.23 and P/S of 0.96, but faces fundamental challenges including negative net income margin of -4.89% and declining revenue trends from $19.5B in 2025 to projected $18.3B in 2026. Recent CEO transition to Dana McNabb and dividend stability at $0.61 quarterly provide some stability amid operational headwinds.
The outlook remains cautious with Wall Street showing mixed sentiment - 61% hold ratings but $36 consensus target suggests 13% upside. Key risks include ongoing margin pressure, competitive threats in packaged foods, and macroeconomic sensitivity. The high 7% dividend yield offers income appeal but sustainability concerns persist given negative profitability metrics and cash flow challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About General Mills, Inc.
General Mills is a leading global packaged food company that produces snacks, cereal, convenient meals, yogurt, dough, baking mixes and ingredients, pet food, and superpremium ice cream. Its largest brands are Nature Valley, Cheerios, Old El Paso, Yoplait, Pillsbury, Betty Crocker, BLUE, and Haagen-Dazs. In fiscal 2022, 77% of its revenue was derived from the United States, although the company also operates in Canada, Europe, Australia, Asia, and Latin America. While most of General Mills' products are sold through retail stores to consumers, the company also sells products into the food-service channel and the commercial baking industry.
Read more on GIS →
